Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective

Lipton, R.B., Brennan, A. orcid.org/0000-0002-1025-312X, Palmer, S. et al. (7 more authors) (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics (JME). pp. 1-10. ISSN 1369-6998

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of Medical Economics on 03 Apr 2018, available online: https://doi.org/10.1080/13696998.2018.1457533
Keywords: CGRP; I10, I19; Value based-price; chronic migraine; cost-effectiveness analysis; economic evaluation; episodic migraine; erenumab; indirect costs; productivity
Dates:
  • Published (online): 3 April 2018
  • Accepted: 21 March 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 13 Jun 2018 10:10
Last Modified: 03 Apr 2019 00:46
Published Version: https://doi.org/10.1080/13696998.2018.1457533
Status: Published online
Publisher: Taylor & Francis
Refereed: Yes
Identification Number: https://doi.org/10.1080/13696998.2018.1457533
Related URLs:

Share / Export

Statistics